Breast cancer drug boosts leukemia treatment, OHSU-led study finds

RNA splicing errors drive leukemia, UMiami-led study finds

A study from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, reveals how two genetic mutations, IDH2 and SRSF2, cooperate to erroneously splice RNA messages and disrupt the cell’s identity.

January 09, 2026

Vol.52 No.1

Clinical Roundup

Researchers decipher mechanism enabling breast cancer to metastasize to the brain

A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, found a mechanism that allows breast cancer to send metastases to the brain. The findings could enable the development of new drugs and personalized monitoring for early detection and treatment of brain metastases.

January 09, 2026

Vol.52 No.1

Drugs & Targets

FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer

FDA granted breakthrough therapy designation to Enhertu (trastuzumab deruxtecan) for adult patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment and high risk of disease recurrence.

January 09, 2026

Vol.52 No.1

Drugs & Targets

Dark Blue Therapeutics acquired by Amgen for up to $840M

Dark Blue Therapeutics was acquired by Amgen.

January 09, 2026

Vol.52 No.1

Podcast

Otis Brawley looks back on a year of great science and greater challenges

In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA.

December 31, 2025

Clinical Roundup

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.

December 19, 2025

Vol.51 No.46

Breast cancer drug boosts leukemia treatment, OHSU-led study finds

YOU MAY BE INTERESTED IN

RNA splicing errors drive leukemia, UMiami-led study finds

Researchers decipher mechanism enabling breast cancer to metastasize to the brain

FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer

Dark Blue Therapeutics acquired by Amgen for up to $840M

Otis Brawley looks back on a year of great science and greater challenges

Similar results reported in comparison of pirtobrutinib vs. ibrutinib to treat CLL, SLL, OSU study finds

Renew today!

Subscriber content

Never miss an issue!

Login